Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 17,24 € (+154,28 %). Medianen er 15,43 € (+127,58 %).
| Køb |
23 |
| Behold |
6 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
BioCryst gains pediatric ORLADEYO approval in Japan, expanding global pediatric franchise
Japan approved once-daily ORLADEYO for hereditary angioedema patients aged 2–12, making it the only oral pediatric prophylactic in that market and strengthening BioCryst's international growth runway. The company has begun US granule shipments and now has ORLADEYO cleared in over 45 countries, while Q2 revenue rose 34% to $218.3 million and cash totaled $354.0 million with positive free cash flow. Management left full-year ORLADEYO guidance unchanged and notes that commercial uptake in Japan depends on the National Health Insurance pricing process; recent revenue growth was also supported by a one-time € licensing payment for navenibart. BioCryst is shifting to an external-licensing R&D model and streamlining operations, which raises execution risk around pipeline assets and international launches. » Mere på finance.yahoo.com
BioCryst turns profitable on Orladeyo and pursues rare-disease acquisitions
BioCryst reported sustained profitability driven by hereditary angioedema drug Orladeyo and expects up to $645 million in sales for 2026, enabling management to fund further rare-disease deals without relying on equity raises. The company has already acquired Astria, adding late-stage candidate navenibart with pivotal data expected in 2027. Financial constraints remain, including negative shareholders' equity and about $822 million in term-loan and royalty obligations, leaving limited room for execution risk if Orladeyo growth slows or acquisitions disappoint. » Mere på finance.yahoo.com
BioCryst receives approval in Japan for HAE drug in young children
The Japanese Ministry of Health has approved ORLADEYO (berotralstat) for prophylactic treatment of hereditary angioedema (HAE) in patients aged 2 to under 12 years. The oral granule formulation showed a consistent safety profile and was generally well tolerated in the APeX-P study of 29 children; the most common treatment-related adverse event was nasopharyngitis. BioCryst will launch the drug in Japan with distribution partner OrphanPacific after completion of pricing and reimbursement processes; approval applications for the same indication are pending with the EMA and Health Canada. » Mere på de.investing.com
BioCryst draws acquisition interest after first profitable year and strong Q2 growth
BioCryst reported its first full year of profitability in 2025 and Q2 2026 revenue rose 33.6% to $218.25 million, supported by Orladeyo which generated $158.2 million in the quarter. The company holds $352.6 million in cash and recently added navenibart via acquisition, with pivotal readout due Q3 2027, sparking takeover speculation. Takeda tops the list of potential strategic buyers given the threat to Takhzyro, followed by AstraZeneca; private equity interest exists but is constrained by BioCryst’s negative shareholders' equity and debt obligations. Analysts remain positive with a consensus target of $20.82 and market attention will focus on navenibart data and any 13D activity. » Mere på finance.yahoo.com
BioCryst Pharmaceuticals raises 2026 revenue guidance, starts pediatric ORLADEYO shipments and ends internal discovery
BioCryst Pharmaceuticals reported Q2 ORLADEYO revenue of $158.2 million, up 10% year over year, and began shipping pediatric oral-pellet prescriptions with 47 scripts by July 31. The company maintained its 2026 ORLADEYO guidance of $625 million to $645 million and raised total 2026 revenue guidance to $690 million to $715 million. BioCryst completed enrollment in the pivotal ALPHA-ORBIT navenibart trial with top-line data expected in Q3 2027, and kept BCX17725 on track for early 2026 data. Management cut 2026 non-GAAP operating-cost guidance to $420 million–$440 million after deciding to end internal drug discovery and close its Birmingham research facility, and reported more than $350 million in cash and investments. » Mere på finance.yahoo.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 159,17 mio. | 17,19 % |
| Bruttofortjeneste | 157,78 mio. | 18,03 % |
| Nettoresultat | 33,47 mio. | 204,54 % |
| EBITDA | 44,11 mio. | 61,13 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,74 mia. € |
Antal aktier | 257,3 mio. |
Højeste/laveste i 52 uger | 10,18 € - 5,65 € |
| Udbytte | Nej |
Beta | 0,54 |
P/E (PE Ratio) | -5,52 |
PEG (PEG Ratio) | 0,00 |
K/I (PB Ratio) | -4,79 |
P/S (PS Ratio) | 1,99 |
Virksomhedsprofil
BioCryst Pharmaceuticals, Inc., et biotekselskab, opdager nye, orale og små-molekylære lægemidler. Selskabet markedsfører peramivir-injektion, en intravenøs neuraminidasehæmmer til behandling af akut ukompliceret influenza under navnene RAPIVAB, RAPIACTA og PERAMIFLU; samt ORLADEYO, en oral serinprotease-hæmmer til behandling af hereditært angioødem. Selskabet udvikler desuden BCX9930, en oral factor D-hæmmer, som er i fase II-klinisk forsøg for komplementmedierede sygdomme; BCX9250, en oral activin receptor-like kinase-2-hæmmer, som er i fase I-klinisk forsøg til behandling af fibrodysplasia ossificans progressiva; og Galidesivir, en RNA-afhængig RNA-polymerasehæmmer, som er i fase I-klinisk forsøg til behandling af forskellige RNA-virus, herunder Marburg, gul feber, Ebola og Zika. Selskabet har samarbejds- og in-licensaftaler med Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; U.S. Department of Health and Human Services; og The University of Alabama at Birmingham, samt Albert Einstein College of Medicine of Yeshiva University og Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. blev grundlagt i 1986 og har hovedkontor i Durham, North Carolina.
| Navn | BioCryst Pharmaceuticals |
| CEO | Charles K. Gayer |
| Hjemsted | Durham,
nc USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 04.03.1994 |
| Medarbejdere | 435 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | BCRX |
Frankfurt | BO1.F |
Düsseldorf | BO1.DU |
SIX | BO1.SW |
München | BO1.MU |